A Single Blind, Placebo Controlled, Parallel Group, Single Ascending Intravenous Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB-240563 (Mepolizumab) in Healthy Japanese Male Subjects.

Trial Profile

A Single Blind, Placebo Controlled, Parallel Group, Single Ascending Intravenous Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB-240563 (Mepolizumab) in Healthy Japanese Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma; Hypereosinophilic syndrome; Nasal polyps; Obstructive airway disorders; Oesophagitis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Mar 2016 Results published in the Clinical Pharmacology in Drug Development
    • 19 Jan 2012 Planned End Date changed from 1 Apr 2012 to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top